hta_admin | Health Technology Assessment Division

[Department Memorandum No. 2021- 0317] Non-inclusion of Pazopanib as a Second-line Treatment for Metastatic Soft Tissue (mSTS) Sarcoma in the Philippine National Formulary (PNF)

Posted on July 21, 2021

[Department Circular No. 2021- 0273] HTAC Issuance on Acceptance and processing of Health Technologies under Monitored Release with Phase IV Trial Data

Posted on July 20, 2021

Preliminary Recommendation on Two-Dose Inactivated Polio Vaccine (IPV)

Posted on July 13, 2021

Document link: MEDICINES RECOMMENDED FOR INCLUSION IN THE PHILIPPINE NATIONAL FORMULARY (PNF) (Proponents may submit appeals to hta@doh.gov.ph until 28 July 2021.) Document Preview:

[Department Memorandum No. 2021- 0294] Non-inclusion of Lapatinib in the Philippine National Formulary

Posted on July 5, 2021

Call for Interested Parties

Posted on July 5, 2021

Health Technology Assessment (HTA) research agenda 2021 Pursuant to the Universal Health Care (UHC) Act, all health technologies that the government will implement and cover shall undergo health technology assessment (HTA). This aims to ensure the rational utilization of various health technologies that will be funded by the government. In this regard, a collaborative approach continue reading : Call for Interested Parties